18F-fluoro-deoxyglucose PET for monitoring treatment in sarcoidosis.
Mortensen
Jann
J
Department of Clinical Physiology, Nuclear Medicine and PET, Rigshospitalet, Copenhagen University Hospital, Denmark. jannmortensen@rh.hosp.dk
Loft
Annika
A
Baslund
Bo
B
D000328:Adult; D005260:Female; D019788:Fluorodeoxyglucose F18; D005938:Glucocorticoids / Q000627:therapeutic use*; D006801:Humans; D008279:Magnetic Resonance Imaging; D010902:Pituitary Gland / Q000000981:diagnostic imaging / Q000473:pathology; D049268:Positron-Emission Tomography / Q000379:methods*; D011239:Prednisolone / Q000627:therapeutic use*; D019275:Radiopharmaceuticals; D012507:Sarcoidosis / Q000175:diagnosis* / Q000188:drug therapy*; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
D005938:Glucocorticoids; D019275:Radiopharmaceuticals; D014409:Tumor Necrosis Factor-alpha; D019788:Fluorodeoxyglucose F18; D011239:Prednisolone